Production (Stage)
Sharp Therapeutics Corp.
SHRXF
$1.29
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 52.98% | -19.22% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.79% | 12.41% | -- | -- | -- |
| Operating Income | -41.79% | -12.41% | -- | -- | -- |
| Income Before Tax | -33.23% | 8.91% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.23% | 8.91% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.23% | 8.91% | -- | -- | -- |
| EBIT | -41.79% | -12.41% | -- | -- | -- |
| EBITDA | -44.90% | -15.91% | -- | -- | -- |
| EPS Basic | 13.94% | -75.34% | -- | -- | -- |
| Normalized Basic EPS | 12.75% | -52.85% | -- | -- | -- |
| EPS Diluted | 13.94% | -75.34% | -- | -- | -- |
| Normalized Diluted EPS | 12.75% | -52.85% | -- | -- | -- |
| Average Basic Shares Outstanding | 268.70% | 107.12% | -- | -- | -- |
| Average Diluted Shares Outstanding | 268.70% | 107.12% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |